cIAP-2/HIAP-1 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB100-56132

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NB100-56132
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot

Cited:

IF/IHC

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

This product is unpurified. The exact concentration of antibody is not quantifiable.

View all cIAP-2/HIAP-1 Antibodies »

Product Specifications

Immunogen

A synthetic peptide corresponding to amino acids 152-172 (QDFSALMRSSYHCAMNNENAR) of human cIAP2 was used as immunogen (NP_892007).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for cIAP-2/HIAP-1 Antibody

Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132]

Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132]

Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132] - Paraffin-embedded formalin-fixed normal human brain tissue cores from a microarray at 1:2000. A) Tissue cores. A1 and A2) successively higher magnificatons of a tissue core from A. Hematoxylin-eosin counterstain.
Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132]

Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132]

Immunohistochemistry: cIAP-2/HIAP-1 Antibody [NB100-56132] - Paraffin-embedded formalin-fixed tissue at 1:2000. A) Human brain tumor microarray showing differential expression of ccIAP-2/HIAP-1. B-E) Higher magnification of selected high grade brain tumor tissue cores from A. Tumor types: B) PNET, C)ependymoblastoma, D) anaplastic oliogdendroglioma, E) glioblastoma multiforme. Strong staining in high grade brain tumors implies malignancy-associated deregulated cIAP2 expression. Hematoxylin-eosin counterstain.

Applications for cIAP-2/HIAP-1 Antibody

Application
Recommended Usage

Immunohistochemistry

1:10-1:500

Immunohistochemistry-Frozen

1:10-1:500

Immunohistochemistry-Paraffin

1:1000-1:5000

Immunoprecipitation

1:50-1:200

Western Blot

1:1000-1:2000

Formulation, Preparation, and Storage

Purification

Unpurified

Formulation

Neat whole antisera

Preservative

0.05% Sodium Azide

Concentration

This product is unpurified. The exact concentration of antibody is not quantifiable.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: cIAP-2/HIAP-1

cIAP2 (API2, BIRC3, HIAP2, MIHC) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria dependent and independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including cIAP2, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubiquitination. Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. The IAPs, including cIAP2, have widespread tissue protein expression, with expression levels and subcellular localization patterns differing depending on the cell lineage (see Vischioni et al. 2005 for a comprehensive study). cIAP2-MALT (API2-MALT1) fusion proteins have been implicated in the molecular pathology of mucosa associated lymphoid tissue (MALT) lymphoma (reviewed in Hosokawa, 2005). AP12-MALT fusion proteins are found in a subset of patients with MALT lymphoma. They are generated by chromosomal translocations whereby the N-terminal portion of AP12 (including the BIR domains) is linked to the C-terminal portion of MALT1 (containing at least an immunoglobulin-like domain and a caspase domain). Several variants of the API2-MALT1 fusion proteins can occur in MALT1 lymphoma patients depending on the chromosomal breakpoints. It is thought that AP12-MALT1 can enhance the activation of NK-kB signaling, which may be relevant to the pathology of MALT lymphomas. This antibody recognizes cIAP2, human cIAP2 is a 604 amino acid protein. This antibody should also recognize AP12-MALT1 fusion proteins assuming that they contain the cIAP2 peptide sequence (QDFSALMRSSYHCAMNNENAR) used for immunogen. The AP12-MALT1 fusion proteins is listed as an 1140 amino acid protein, GenBank no. AAD46161.1. However, users should keep in mind that the actual amino acid length of AP12-MALT1 fusion proteins may vary depending on the chromosomal breakpoints

Alternate Names

BIRC3, cIAP2, HIAP-1, MIHC

Entrez Gene IDs

330 (Human)

Gene Symbol

BIRC3

UniProt

Q13489

Additional cIAP-2/HIAP-1 Products

Product Documents for cIAP-2/HIAP-1 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for cIAP-2/HIAP-1 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.